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Abstract
Background: The primary objective of this study was to assess the efficacy, under field conditions, of a novel
ready-to use Mycoplasma hyopneumoniae (M hyo) and Porcine circovirus type 2 (PCV2) combination vaccine given
to piglets as one vaccination (1-shot) at 3 weeks of age. The study was carried out according to a controlled,
randomised, and blinded design in a Greek pig herd with clinical M. hyo and subclinical PCV2 infection. Moreover,
based on serology at the time of vaccination, the average PCV2 titre was 9.15 log2 and represented the level of
maternally derived antibodies (MDA). In total 602 healthy suckling piglets, originating from 4 weekly farrowing
batches were allocated randomly, within litters, to one of two groups. The pigs in one group were vaccinated with
the test product and the other pigs were injected with saline.
Results: Vaccination significantly reduced lesions of craneo-ventral pulmonary consolidation in vaccinated group
[expressed as lung lesion score (LLS)] (Mixed model ANOVA: p < 0.0001). The mean LLS was 17.1 in the controls and
10.6 in the treatment group, respectively. The average daily weight gain (ADWG) during the finishing (54 g better in
the treatment group) and whole study period (34 g better in vaccinated animals) was significantly greater in
vaccinated than control pigs. The vaccinated pigs had a significant reduction of PCV2 viraemia when compared
with the controls.
Conclusions: The test product was considered effective in the face of average MDA, based on significantly reduced
severity of LLS and PCV2 viral load, as well as improved ADWG in vaccinated versus control pigs.
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Background
Mycoplasma hyopneumoniae (M. hyo) and Porcine cir-
covirus type 2 (PCV2) are two of the most important
pathogens in swine. Economical impact of M. hyo and
PCV2 infections in swine farms worldwide can be con-
sidered as significant [1, 2]. Enzootic pneumonia (EP) is
a major clinical respiratory disease in swine [3]. It is
characterized by non-productive cough, growth retard-
ation with higher feed conversion and decreased body
weight gain and craneo-ventral pulmonary consolidation.
M. hyo infection along with other pathogens such as
Pasteurella multocida and other is the aetiology of EP.
Further implication of other pathogens (e.g. viral agents)
in EP, result in the creation of the Porcine Respiratory
Disease Complex (PRDC) [2, 4–9].
The usual method for protection against EP in swine
farms is routine vaccination with various commercial vac-
cines either as one-shot or as two-shot administration
schemes [9]. A number of previously reported studies
have emphasized the benefits from such routine vaccin-
ation programmes either after intramuscular [10, 11] or
intradermal administration [3, 11], against the nega-
tive impact of EP on health and productive parame-
ters of infected pigs. However, despite the extensive
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vaccination efforts in the vast majority of swine farms
worldwide, M. hyo remains a major problem [12].
The PCV2 has been associated with post weaning multi-
systemic wasting syndrome (PMWS) porcine dermatitis
and nephropathy syndrome (PDNS), porcine respiratory
disease complex (PRDC) and the occurrence of prolifera-
tive and necrotizing pneumonia, as well as reproductive
failure and enteritis [13, 14]. All the above-mentioned
conditions along with subclinical PCVD cases are de-
scribed as porcine circovirus diseases (PCVD) and cause
great economical losses in pig production worldwide [14].
During the past few years a number of commercially used
vaccines have been the main control mechanism against
PCVD in swine farms [15]. Previous reports suggest a
varying but nevertheless positive outcome of vaccination
against PCV2 [13, 16–18]. However, due to its transmis-
sion characteristics, the virus "stays" within pig farms for
years without any further need for re-introduction due to
frequent pig movements within farm compartments and
the continuous renewal of susceptible animals [19].
On the other hand, the interference of PCV2 mater-
nally derived antibodies (MDA) in the priming of piglets'
immune response after vaccination is a not fully quanti-
fied fact. It has been reported that this effect depends on
the level of MDA. Previous research suggests that optimal
vaccination strategies against PCV2 must take into con-
sideration the correct time of vaccination, in order to have
a 3-side balance including the time needed for immune
response prior to exposure to pathogens, the time needed
for MDA to decline and the maturation of the piglets
immune system to respond adequately [14, 17].
The aim of this study was to investigate the efficacy of a
novel combination vaccine against EP and PCVD simul-
taneously as a one-shot vaccination at 3 weeks of age
under field conditions. The assessment of the test product's
efficacy under the interference of average PCV2 MDA level
was also a significant research target in this study.
Results
Body weight and ADWG
The ADWG during the finishing and over the whole study
period was significantly higher in the vaccinated group
when compared with controls. Specifically, vaccinated ani-
mals showed improved mean ADWG by 54 ± 9 g/day dur-
ing the finishing period and 34 ± 6 g/day during the whole
trial period, in comparison to the control group. The
ADWG differences among groups were not statistically
significant in the nursery period. Although mean body
weight among the two groups was not significantly differ-
ent at three time points of the study, body weight at
slaughter age was 4.9 kg greater in vaccinated animals.
The mean body weight at three different time points and
the adjusted mean ADWG per vaccination group and per
period are presented in Table 1.
Lung and pleuritis lesions
Vaccination with the test product significantly reduced le-
sions of craneo-ventral pulmonary consolidation, expressed
as mean lung lesion score (LLS), from 17.1 (standard devi-
ation: 11.1) in the control group to 10.6 (standard devi-
ation: 9.6) in vaccinated pigs (mixed model ANOVA: p <
0.0001). The incidence of pleuritis lesions (score ≥1) did
not differ significantly among groups [Cochran Mantel
Haenszel (CMH) test: p = 0.0609], and it was 29 % in the
controls and 21 % in the vaccinated group, respectively.
Mortality and morbidity
A total of 34 animals (17 vaccinated and 17 controls) died
or were culled during the study period. Mortality was as-
sociated with enteritis (diarrhoea) in 10 animals (5 in each
group) during the nursery period and respiratory disease
in 11 animals (5 in vaccinated group and 6 controls) dur-
ing the growing/finishing period (with findings of fibrino-
necrotizing pleuropneumonia and fibrinous polyserositis).
Thirteen animals died due to other reasons (eg spine
injury, or trauma).
As for morbidity (defined as the proportion of animals
that received individual medication), forty-nine (49) ani-
mals in the vaccinated group (16.2 %) and 58 controls
(19.4 %) received individual medication. Specifically, 17
animals from the vaccinated group and 25 control pigs
showed clinical signs of gastrointestinal disease
(diarrhea), while 31 treated animals and 32 control pigs
showed severe respiratory signs and were treated indi-
vidually. Morbidity comparison among groups did not
reveal statistical differences (CMH test: p = 0.3031).
Blood serum tests
On day 0 of the study, the mean level of PCV2 anti-
bodies was 9.2 log2 for the vaccinated animals, and 9.1
log2 for the controls (mean of all trial piglets was 9.15
log2). Serology of PCV2 and M. hyo confirmed the
presence of PCV2 and M. hyo field infections. At the time
of vaccination, 42 % of the vaccinated piglets and 45 % of
controls were seropositive for M hyo. M. hyo serological
seroconversion occurred after the 10th week of age.
Throughout the study the percentage of M hyo seroposi-
tive pigs was higher in the vaccinated groups than in the
controls (Fig. 1). Analysis revealed significant differences
among groups in samples from weeks 14, 18 and 22 (p <
0.0001, p = 0.0007, and p = 0.0196, respectively).
The mean antibody titres against PCV2 in both groups
increased between 18 and 22 weeks of the study, indicating
a field infection during the finishing period. The titres in
the vaccinated group were higher than in the controls from
6 weeks until the end of the study. The results are sum-
marised in Fig. 2. Statistically significant differences were
observed in samples from weeks 10, 14, 18 and 22 (p <
0.0001, p < 0.0001, p = 0.0013, and p < 0.0001, respectively).
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The vaccinated animals showed a significant reduction
in viraemia when compared with controls. The results of
quantitative real-time PCR (qPCR) for PCV2 viral DNA
(samples from week 18 and 22 of the study) showed that
the mean area under the curve [AUC: log10 DNA copies
PCV2 /per μl DNA extract * week; defined as the sum of
segments, each defined by 2 measurement time points
in the viraemia plot per subject] was less than one third
of the control group (1.47 vs. 5.42; ANOVA p < 0.0001).
The results, expressed as the mean log10 DNA copies
per μl DNA extract and the percentage of PCV2 positive
samples are summarised in Table 2.
Furthermore, with regard to other pathogens tested
(samples of 14th, 18th and 22nd week of the study), it
was demonstrated that towards the end of the study
nearly all pigs were seropositive for PRRS virus and had
rising antibody titres against the outer membrane pro-
tein (OMP) of APP. Low titres were measured for anti-
bodies against swine influenza viruses (data not shown).
Discussion
Study results support that the test vaccine administered
at 3 weeks of age, can induce a significant immune re-
sponse against M hyo and PCV2, and can play a major
role in improving LLS and ADWG of vaccinated pigs in
comparison with non-vaccinated animals. The vaccina-
tions scheme used in this trial successfully induced im-
munity of piglets as seen by antibody response through
the course of the study. Thus, adequate immune priming
against M hyo and PCV2 is considered the main factor
Table 1 Mean body weight and average daily weight gain (ADWG), by vaccination group and time point-period
Time point or period Group
Porcilis PCV M Hyo (nc = 303) Control (n = 299)
Body weight (kg)
One week old 2.2 ± 0.6 (n = 303) 2.2 ± 0.6 (n = 299)
Transfer to finishing 18.5 ± 3.6 (n = 297) 18.3 ± 3.6 (n = 293)
Pre-slaughter 96.6 ± 12.1 (n = 256) 91.7 ± 11.3 (n = 255)
ADWG (g/day)║
Porcilis PCV M Hyo Control
Nursery period 286 ± 11a 282 ± 11a
Finishing period 816 ± 16a 762 ± 16b
Overall 619 ± 9a 585 ± 9b
Mean body weight expressed as kg ± standard deviation and ADWG presented as g/day. Mean ADWG is adjusted for sow, sex, batch and initial body weight ± standard
error of the mean
Level of significance (ANOVA) among superscripts : Nursery period=0.3944, Finishing period ab< 0.0001, Overall ab< 0.0001
cn = number of animals
Fig. 1 M. hyo serological results, by vaccination group and week of age legend: Statistical differences levels: Week 3: p = 0.5789, Week 6 p = 0.5372,
Week 10 p = 0.0827, Week 14 p < 0.0001, Week 18 p = 0.0007, Week 22 p = 0.0196
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that lead to better LLS and ADWG in the vaccinated
group. Similar results have been shown in other research
efforts with one-shot vaccination against each of those
pathogens separately [3, 15, 16, 20]. Our results suggest
that one-shot vaccination with a ready-to-use combination
vaccine against both pathogens at 3 weeks of age signifi-
cantly benefits the primary parameters investigated in this
study, and in a similar way as in separate vaccination.
In addition, PCV2 viraemia results (expressed as AUC)
were significantly better in the vaccinated group when
compared with controls on both the 18th and the 22nd
week of age. Results of increasing PCV2 antibody ti-
tres after the 18th week, in both groups, suggest a
detectable PCV2 occurrence at a time point around
14 weeks after vaccination. The PCV2 antibody titre
alterations (greater mean levels in vaccinated animals
when compared with controls), along with strong vir-
aemia reduction during late fattening in vaccinated
pigs, clearly suggest a positive impact of the test
vaccine for the control of subclinical PCV2.
Due to the nature of the test vaccine, a direct compari-
son with results from studies in which M hyo and PCV2
vaccines were administered separately cannot be done.
On the other hand, the interference of PCV2 MDA in
active immunization of piglets after vaccination is dis-
cussed as a controversial issue. It has been stated that
maternal antibodies can affect the age of PCV2 infection
[19] while it has also been demonstrated that high PCV2
MDA levels (≥10 log2) could interfere with piglets' active
seroconversion at vaccination without having a negative
impact on vaccine efficacy [13]. Nevertheless, a negative
MDA effect on humoral immune response of piglets
could not be supported by the findings of this study.
Moreover, it could be hypothesized that the largest
part of ADWG improvement should be attributed to the
effect of vaccination against M. hyo since the trial farm
had more severe EP than PCVD. Similarly, differences in
body weight at slaughter could also be attributed to bet-
ter control of EP in vaccinated pigs. Even if those differ-
ences on body weight were not statistically significant,
they show a noteworthy tendency for improvement of
approximately 4.9 kg live weight at slaughter, which is
extremely important from a financial standpoint. How-
ever a future research effort under field conditions with
severe PCVD and less clinically severe EP would be
needed to elucidate the effect of each pathogen on
ADWG and body weight improvement.
Furthermore, although not in the scope of this study,
the use of the test product for immunization of pigs
against two significant pathogens can be considered
more practical since there is less labour, handling and
injections (less stressful for the animals) needed.
Additionally, since no local or systemic reactions were
observed (data not shown), the test product was consid-
ered safe under the conditions used in this study.
Conclusions
The Porcilis PCV M Hyo combination vaccine was ef-
fective for use in piglets at 3 weeks of age. Vaccination
Fig. 2 PCV2 serological results, by vaccination group and week of age legend: Statistical differences levels: Week 3: p = 0.9162, Week 6 p = 0.3069,
Week 10 p < 0.0001, Week 14 p < 0.0001, Week 18 p = 0.0013, Week 22 p < 0.0001
Table 2 PCV2 viraemia results, by vaccination group and week
of age
Week of age Porcilis PCV M Hyo Control
18 0.63 (20 %) 1.14 (28 %)
22 0.35 (14 %) 2.20 (64 %)
AUCc 1.47/0.0a 5.42/5.36b
Mean log10 DNA copies PCV2/per μl DNA extract and percentage (in parenthesis)
of PCV2 positive serum samples, as well as area under the curve (AUC), by
vaccination group and week of age
cAUC expressed as log10 DNA-copies *week. AUC results are presented as
Mean/Median
One DNA copy/μl DNA is equivalent to 250 DNA copies per ml of serum
Level of significance (ANOVA) among superscripts ab: p < 0.0001
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resulted in greater percentage of M hyo seropositive pigs
and increased PCV2 antibody titres, for the total trial
period, as well as significant reduction of the severity of
LLS and improvement of ADWG during the finishing
and the overall study period, along with significant
reduction of the PCV2 viral load.
Methods
Trial design
The study was carried out according to a controlled,
randomised, and blinded design in a Greek pig herd with
a history of M. hyo infection and subclinical PCV2 co-
infection. In total 602 healthy 3 week old suckling piglets
(study day 0), originating from 4 weekly farrowing
batches were allocated randomly, within litters, to one of
two groups (vaccinated or control). Control group ani-
mals (299 pigs) received saline intramuscular injection
on study day 0. At the same time point, the vaccinated
group (303 animals) received 2 ml of the test product.
All injections were applied intramuscularly in the neck
area. The animals included in the study were fed and re-
ceived water according to standard farm procedures.
The sows of which piglets were included in the study
were routinely vaccinated against PCV2 (vaccination at
2–3 weeks before parturition), Aujeszky’s disease virus,
porcine reproductive and respiratory syndrome virus
(PRRSV), porcine parvovirus, Erysipelothrix rhusio-
pathiae, atrophic rhinitis and Escherihia coli.
The study was performed in conformity with the require-
ments of EU note for guidance “Specific Requirements for
the production and control of Pig Live and Inactivated
Viral and Bacterial Vaccines (III/3362/92)”, Ph.Eur General
Chapter 5.2.7 “Evaluation of efficacy of veterinary vaccines
and immunosera” and Ph.Eur Monograph 2448 “Porcine
enzootic pneumonia vaccine (inactivated)”. The procedures
in this clinical study were performed according to the Code
of practice for the Conduct of Clinical trials for Veterinary
Medical Products [21] and the animals were maintained in
accordance with National and European Animal Welfare
requirements [22, 23].
Test product
The test product is a new ready-to-use combination vac-
cine consisting of PCV2 ORF2 expressed in Baculovirus
and inactivated M. hyo strain J in Emunade® adjuvant.
The present study was done to evaluate field efficacy
of this new vaccine in a farm with concurrent clinical
M. hyo and subclinical PCV2 infection (both occurring
after natural exposure to the pathogens) as confirmed in a
pre-trial screening that included lung lesion scoring at
slaughter for M. hyo and PCR testing of blood samples for
PCV2 (data not shown).
Parameters
Efficacy parameters were LLS, ADWG, mortality, mor-
bidity, PCV2 viraemia, and pleuritis lesions. To obtain
the efficacy data, the pigs were weighed individually at ap-
proximately 1 week of age, at transfer to the finishing unit
(week 9–10 of age), and before slaughter (week 21–22 of
age). Last weighing pre-slaughter was performed in 256
vaccinated pigs and 255 control animals.
The lungs were examined individually at slaughter to
assess LLS and pleuritis lesions score according to the
method of Goodwin and Whittlestone (1973) [24]. In
total, 255 lungs from vaccinated animals and 254 lungs
from control pigs were examined. The lungs were scored
for typical M hyo. lesions. For each lung lobe, the per-
centage of the surface with signs of typical M hyo associ-
ated inflammation (consolidated, grey to purple coloured)
was estimated. These percentages (in fact proportions)
were multiplied with the weighing factor of each lobe [24]
and added up to obtain the total LLS. Thus, the minimum
lung lesion score for an animal was 0 and the maximum
55. Also pleuritis lesions were investigated and scored
from 0 to 2 (0 = no pleuritis lesions, 1 = topical adhesions
(spots) or 2 = larger adhesions). Medication was recorded
and necropsy was performed in pigs that died during the
study, unless the cause of death was clear and could not
be related to PCV2 or M hyo infection and vaccination
(eg crushed suckling piglets), to establish the cause of
death, based on gross lesions.
Blood sampling investigation
Blood samples were collected from 45 piglets per group
at regular intervals (3, 6, 10, 14, 18, 22 week of age) and
the sera were tested with ELISA for antibodies against
PCV2 [25] and M. hyo (Swine HerdChek M. Hyo
IDEXX). The blood samples collected at 18 and 22 weeks
were tested by qPCR for PCV2 DNA. The blood samples
taken at weeks 14, 18 and 22 of the study were also
tested for antibodies against APP with the APP OMP
ELISA [26], PRRSV (IDEXX PRRS X3 Ab Test), and
swine influenza viruses (H1N1, H1N2 and H2N3) by HI
test [27].
For PCV2 an in-house ELISA of MSD Animal Health
was used as previously described [25]. Titres in the
PCV2 ELISA were expressed as the reciprocal of the
serum dilution with a calculated extinction value of 50 %
maximum extinction. Based on the serological results,
the appropriate samples (i.e. time points) were selected
for determination of the PCV2 viral load in the serum.
The amount of PCV2 genomic DNA was quantified by
qPCR as previously described [25]. The results were
expressed as log10 genome copies/μl DNA extract. One
copy/μl DNA extract is equivalent to 250 copies per ml
of serum. If the viral load was below the detection limit
of 2.00 log10 copies/μl DNA extract, the result was
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considered negative and set at zero (0). The ELISA for
M. hyo and PRRS were carried out as recommended by
the supplier. The results were expressed as ‘positive’,
‘inconclusive’ or ‘negative’.
Statistical methods
The pig was the statistical unit and level of significance
was set at 0.05. Descriptive statistics (frequency tables,
means, standard deviations etc.) were used to summarize
results. Specifically, LLS and ADWG comparisons
among groups were tested in a mixed model ANOVA
(lung lesions log transformed before analysis). For LLS
comparisons, the vaccination group was included as
fixed effect and the sow and production batch as ran-
dom effects. For ADWG comparisons the vaccination
group and gender with their interaction were included
as fixed effects and sow and production batch as random
effects. The body weight at one week of age was
included in the model as a covariate.
The AUC (Area Under the Curve) was used for the
analysis of PCV2 viraemia data. In the viraemia plot per
subject, the y-axis represents the viraemia level at a
given time point and the x-axis the time (in weeks) after
vaccination. The AUC segment defined by 2 measure-
ment time points is therefore expressed as log10 DNA-
copies of PCV2 per μl DNA extract * week of study. The
AUC is calculated by summing the area of these seg-
ments over the entire period in which the samples were
analysed. The data were ranked before analysis by
ANOVA with treatment as factor.
The Cochran Mantel Haenszel method with produc-
tion batch as classification variable was used for the
comparison between groups, as regard to the parameters
pleuritis lesions (absent or present) and morbidity.
PCV2 antibody titres were analysed by mixed model
ANOVA and the proportion of M hyo positive samples
by generalised estimating equation (GEE) followed by LS
means to compare the results between the treatment
groups per week.
Competing interests
The MSD Animal Health (Boxmeer, The Netherlands) funded the trial through
the Research Committee of the Aristotle University of Thessaloniki, Greece
(grant number: 89114 to EDT). All trial materials were supplied by the
funding body and blind serological tests were performed in the laboratories
of MSD Animal Health (Boxmeer, The Netherlands). One of the authors (TN)
is an employee of the funding body.
Authors' contributions
EDT, PT, participated in the design of the study, performed the statistical
analysis and drafted the manuscript, DK, VG IT carried out trial measurements
and assisted on the interpretation of laboratory results TN conceived the
study, participated in its design and coordination, GB carried out pathology
examinations and lung lesion scoring. All authors read and approved the
final manuscript.
Authors' information
EDT is ECPHM diplomate.
Acknowledgements
The authors thank the assistant manager of the trial farm (Suzanna Flora) for
her technical assistance during the course of the study.
Author details
1Farm Animals Clinic, School of Veterinary Medicine, Faculty of Health
Sciences, Aristotle University of Thessaloniki, University Campus, 54124
Thessaloniki, Greece. 2Lagou 59, 41334 Larissa, Greece. 3Clinic of Medicine,
Faculty of Veterinary Medicine, University of Thessaly, Trikalon 224, P.O. Box
199, Karditsa, Greece. 4MSD Animal Health, Clinical Study Team Biologicals,
P.O. Box 315830 AA Boxmeer, The Netherlands. 5Laboratory of Pathology,
School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University
of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
Received: 17 April 2015 Accepted: 15 September 2015
References
1. Chae C. A review of porcine circovirus 2-associated syndromes and diseases.
Vet J. 2005;169:326–36.
2. Maes D, Segales J, Meyns T, Sibila M, Pieters M, Haesebrouck F. Control of
Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol.
2008;126:297–09.
3. Tassis PD, Papatsiros VG, Nell T, Maes D, Alexopoulos C, Kyriakis SC, et al.
Clinical evaluation of intradermal vaccination against porcine enzootic
pneumonia (Mycoplasma hyopneumoniae). Vet Rec. 2012;170:261.
4. Wilson S, Van Brussel L, Saunders G, Runnels P, Taylor L, Fredrickson D, et al.
Vaccination of piglets up to 1 week of age with a single-dose Mycoplasma
hyopneumoniae vaccine induces protective immunity within 2 weeks
against virulent challenge in the presence of maternally derived antibodies.
Clin Vaccine Immunol. 2013;20:720–4.
5. Yagihashi T, Nunoya T, Mitui T, Tajima M. Effect of Mycoplasma
hyopneumoniae infection on the development of Haemophilus pleuro-
pneumoniae pneumonia in pigs. Nihon Juigaku Zasshi. 1984;46:705–13.
6. Thacker E, Minion F. Mycoplasmal diseases. In: Zimmerman J, Karriker L,
Ramirez A, Schwartz K, Stevenson G, editors. Diseases of Swine, 10th ed.
Ames, Iowa, USA: Wiley-Blackwell; 2012. p. 779–88.
7. Ciprian A, Pijoan C, Cruz T, Camacho J, Tortora J, Colmenares G, et al.
Mycoplasma hyopneumoniae increases the susceptibility of pigs to
experimental Pasteurella multocida pneumonia. Can J Vet Res. 1988;52:434–8.
8. Sibila M, Pieters M, Molitor T, Maes D, Haesebrouck F, Segales J. Current
perspectives on the diagnosis and epidemiology of Mycoplasma
hyopneumoniae infection. The Vet J. 2009;181:221–31.
9. Sibila M, Nofrarías M, López-Soria S, Segalés J, Valero O, Espinal A, et al.
Chronological study of Mycoplasma hyop- neumoniae infection,
seroconversion and associated lung lesions in vaccinated and
non- vaccinated pigs. Vet Microbiol. 2007;122:97–07.
10. Kristensen CS, Vinther J, Svensmark B, Bækbo P. A field evaluation of two
vaccines against Mycoplasma hyopneumoniae infection in pigs. Acta Vet
Scand. 2014;56:24.
11. Martelli P, Saleri R, Cavalli V, De Angelis E, Ferrari L, Benetti M, et al. Systemic
and local immune response in pigs intradermally and intramuscularly
injected with inactivated Mycoplasma hyopneumoniae vaccines.
Vet Microbiol. 2014;168:357–64.
12. Hillen S, von Berg S, Köhler K, Reinacher M, Willems H, Reiner G. Occurrence
and severity of lung lesions in slaughter pigs vaccinated against
Mycoplasma hyopneumoniae with different strategies. Prev Vet Med.
2014;113:580–8.
13. Fort M, Sibila M, Pérez-Martín E, Nofrarías M, Mateu E, Segalés J. One dose
of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-
old conventional piglets elicits cell-mediated immunity and significantly
reduces PCV2 viremia in an experimental model. Vaccine. 2009;27:4031–7.
14. Segalés J. Porcine circovirus type 2 (PCV2) infections: clinical signs,
pathology and laboratory diagnosis. Virus Res. 2012;164:10–9.
15. Park C, Seo HW, Han K, Chae C. Comparison of four commercial one-dose
porcine circovirus type 2 (PCV2) vaccines administered to pigs challenged
with PCV2 and porcine reproductive and respiratory syndrome virus at
17 weeks postvaccination to control porcine respiratory disease complex u.
Clin Vaccine Immunol. 2014;21:399–06.
16. Martelli P, Ferrari L, Morganti M, De Angelis E, Bonilauri P, Guazzetti S, et al.
One dose of a porcine circovirus 2 subunit vaccine induces humoral and
Tzika et al. Porcine Health Management  (2015) 1:15 Page 6 of 7
cell-mediated immunity and protects against porcine circovirus-associated
disease under field conditions. Vet Microbiol. 2011;149:339–51.
17. Fort M, Sibila M, Allepuz A, Mateu E, Roerink F, Segalés J. Porcine circovirus
type 2 (PCV2) vaccination of conventional pigs prevents viremia against
PCV2 isolates of different genotypes and geographic origins. Vaccine.
2008;26:1063–71.
18. Opriessnig T, Patterson AR, Elsener J, Meng XJ, Halbur PG. Influence of
maternal antibodies on efficacy of porcine circovirus type 2 (PCV2)
vaccination to protect pigs from experimental infection with PCV2.
Clin Vaccine Immunol. 2008;15:397–01.
19. Rose N, Opriessnig T, Grasland B, Jestin A. Epidemiology and transmission of
porcine circovirus type 2 (PCV2). Virus Res. 2012;164:78–89.
20. Kim D, Kim CH, Han K, Seo HW, Oh Y, Park C, et al. Comparative efficacy of
commercial Mycoplasma hyopneumoniae and porcine circovirus 2 (PCV2)
vaccines in pigs experimentally infected with M. hyopneumoniae and PCV2.
Vaccine. 2011;29:3206–12.
21. EMEA - European Agency for the evaluation of medicinal products,
veterinary medicines and inspections. Guidelines on Statistical Principles for
Veterinary Clinical Trials. In: European Medicines Agency (EMEA). London,
UK: CVMP 816/00 – EMEA CVMP; 2001. p. 6–7.
22. EMEA - European Agency for the evaluation of medicinal products.
Guidelines on Good Clinical Practices. In: European Medicines Agency
(EMEA), CVMP 595 – VICH Topic GL9 (GCP). London, UK: EMEA CVMP;
1998. p. 1–28.
23. FVE (Federation of Veterinarians of Europe). European Veterinary Ethics and
Principles of Conduct. In: Code of Good Veterinary Practice (GVP Code).
Brussels: Federation of Veterinarians of Europe; 2002. p. 4–7.
24. Goodwin RFW, Whittlestone P. Enzootic pneumonia of pigs: immunisation
attempts inoculating M. suipneumoniae antigen by various routes and with
different adjuvants. Br Vet J. 1973;129:456–62.
25. Haake M, Palzer A, Rist B, Weissenbacher-Lang C, Fachinger V, Eggen A,
et al. Influence of age on the effectiveness of PCV2 vaccination in piglets
with high levels of maternally derived antibodies. Vet Microbiol.
2014;168:272–80.
26. Van den Bosch H, Frey J. Interference of outer membrane protein PalA with
protective immunity against Actinobacillus pleuropneumoniae infection in
vaccinated pigs. Vaccine. 2003;21:3601–7.
27. OIE World Organization for Animal Health. Manual of Diagnostic Tests and
Vaccines for Terrestrial Animals 2014, 2: section 2.8.8. Paris, France: World
Organization for Animal Health. p. 1–11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tzika et al. Porcine Health Management  (2015) 1:15 Page 7 of 7
